摘要
目的:探究白三烯调节剂及沙美特罗治疗支气管哮喘患者的临床效果及对患者呼气一氧化氮(fractional exhaled nitric oxide,FeNO)、血清白细胞介素-10(interleukine-10,IL-10)和超敏C反应蛋白(high-sensitive C-reactive protein,hs-CRP)水平的影响。方法:选择2019年3月至2020年3月于我院接受治疗的60例支气管哮喘患者,按照随机数字表法将其均分为研究组与对照组(每组各30例患者)。对照组患者接受沙美特罗治疗,研究组患者在对照组基础上加用白三烯调节剂治疗,对比两组患者治疗前后FeNO、血清IL-10、hs-CRP水平、第1秒用力呼气容积占预计值百分比(the percentage of forced expiratory volume in predicted value,FEV1%)、呼气峰流量(peak expiratory flow,PEF)和哮喘控制测试(asthma control test,ACT)的变化及治疗过程中不良反应的发生情况。结果:治疗后,研究组患者FeNO、血清hs-CRP水平均显著低于对照组,血清IL-10水平、FEV1%、PEF和ACT均明显高于对照组(P<0.05)。两组治疗过程中不良反应的发生率比较差异无统计学意义(P>0.05)。结论:白三烯调节剂联合沙美特罗对支气管炎哮喘具有较好的治疗效果,能够显著改善患者机体炎性状态,同时调节患者的肺功能,且治疗安全性较高。
Objective:To explore the clinical effect of leukotriene modulators and salmeterol in the treatment of patients with bronchial asthma,and to exhale nitric oxide(fractional exhaled nitric oxide,FeNO),serum interleukin-10(IL-10)Effect of high-sensitive C-reactive protein(hs-CRP)level.Methods:60 patients with bronchial asthma who were treated in our hospital from March 2019 to March 2020 were selected.According to the method of random number table,they were divided into experimental group and control group(30 patients in each group).Patients in the control group were treated with salmeterol,and patients in the study group were treated with leukotriene regulator on the basis of the control group,compared with FeNO,serum IL-10,hs-CRP levels,FEV1%,PEF and ACT before and after treatment in the two groups changes and the occurrence of adverse reactions during treatment.Results:After treatment,the levels of FeNO and hs-CRP in the study group were significantly lower than those in the control group,and the levels of serum IL-10,FEV1%,PEF and ACT were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions was no significantly different between the two groups during treatment(P>0.05).Conclusion:Leukotriene combined with salmeterol had a good therapeutic effect on bronchitis and asthma,which could significantly improve the inflammatory state of the patient's body,and at the same time regulate the lung function of patients,and had a high therapeutic safety.
作者
叶新丽
李娜
谷俊
赵珊
高学飞
YE Xin-li;LI Na;GU Jun;ZHAO Shan;GAO Xue-fei(Department of Respiratory Medicine,East Hospital of the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,710089,China;Department of Laboratory Medicine,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,710061,China;Department of Respiratory Medicine,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xi'an,Shaanxi,712000,China)
出处
《现代生物医学进展》
CAS
2021年第8期1479-1483,共5页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(No.81500219)。